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Abstract
Background: To determine whether weight loss is significantly associated with a discontinuation
of treatment for idiopathic intracranial hypertension
Methods: The notes of 36 patients with idiopathic intracranial hypertension under regular review
for at least 12 months by a single neuro-ophthalmologist were retrospectively reviewed. Weight
was recorded at each assessment and weight loss recommended. Treatment was adjusted
according to symptoms, visual function including visual fields and optic disc appearance only.
Patients were divided according to duration of continuous follow-up, and then sub-divided as to
whether they were on or not on treatment at most recent review and whether weight loss had
been achieved compared to presentation. Survival analysis was performed to assess the probability
of remaining on treatment having lost weight.
Results: Considering the patients as 3 groups, those with at least 12 months follow-up (n = 36),
those with at least 18 months follow-up (n = 24) and those with 24 months or more follow-up (n
= 19), only the group with 24 months or more follow-up demonstrated a significant association
between weight loss and stopping systemic treatment (Fisher's exact test, p = 0.04). Survival
analysis demonstrated that the probability of being on treatment at 5 years having gained weight
was 0.63 and having lost weight was 0.38 (log rank test, p = 0.04). The results suggest that final
absolute body mass index is more important than the change in body mass index for patients who
stop treatment (Mann Whitney U, p = 0.05).
Conclusion: This is the first study to demonstrate that weight loss is associated with
discontinuation of treatment. Unlike previous studies, our results suggest that final absolute body
mass index is more important for stopping treatment than a proportional reduction in weight.
Background
Idiopathic intracranial hypertension (IIH) is associated
with elevated body mass index (BMI) [1,2]. Recent weight
gain at presentation and BMI greater than 40 are predic-
tive of greater visual impairment [3-5]. Weight loss, by
dieting or gastric surgery, is associated with normalisation
of central serous fluid (CSF) pressure and improvement in
papilloedema [1,6-9]. Although these are reasonable
short-term measures of disease amelioration, long-term
benefit has yet to be demonstrated.
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several factors. Although CSF pressure is the primary
parameter, intracranial pressure monitoring has shown
that CSF pressure fluctuates widely throughout the day in
IIH [10] such that lumbar puncture provides only limited
information on disease control [3]. Papilloedema is an
important secondary measure but optic disc assessment,
even by scanning laser ophthalmoscopy, does not neces-
sarily differentiate between resolving papilloedema and
secondary optic atrophy [11]. Visual function, especially
visual fields, is a vital parameter but is prone to testing var-
iability and generally can only determine whether there is
disease progression not resolution. Assessment of symp-
toms, particularly headaches, is subject to confounding
factors such that their persistence does not necessarily cor-
relate with disease activity. In order to circumvent these
difficulties, the end point chosen by this study was the
decision by a single neuro-ophthalmologist, based on an
overall assessment of these various factors (excluding the
patient's weight), as to whether continuation of treatment
was required. A particular benefit is that the results pro-
vide information easily conveyed to patients about the
value of weight loss in IIH.
Methods
Case notes were reviewed of patients with a diagnosis of
IIH fulfilling standard diagnostic criteria [12] identified
from a database of patients managed by a single neuro-
ophthalmologist since February 1998. The minimum
required follow-up for inclusion was 12 months. Ethical
approval for this study was granted by the King's College
Hospital Research Ethics Committee. Research was carried
out in compliance with the Helsinki Declaration.
Symptoms, particularly headache, tinnitus and visual dis-
turbance especially transient visual obscurations, visual
acuities, visual fields by Humphrey® 24-2 or 30-2 compu-
terised or Goldmann perimetry, optic disc appearance and
weight were recorded at each clinic visit. Weight measure-
ments were performed by a nurse using manual scales but
without a protocol regarding the amount of clothing that
the patient should be wearing.
Weight loss was recommended to every patient, aiming
for an initial 5% reduction in weight over 3 months. No
specific advice was given as to the method of weight loss,
other than reduction in calorie intake and increase in exer-
cise. Referral to a dietician was arranged if requested or
there was failure to lose weight. Although an influence on
treatment decisions cannot be excluded, weight was not
used as a factor in determining treatment. It was used as a
factor in advising patients on likely prognosis.
Treatment, determined by symptoms, visual function and
optic disc appearance, was primarily acetazolamide, usu-
ally starting at 500 mg/day rising to 1 g/day and occasion-
ally up to 1.5 g/day. Furosemide 20–40 mg/day or if
headaches were troublesome topiramate gradually
increasing to 200 mg/day were used if there was intoler-
ance, lack of efficacy or contraindication to acetazola-
mide. Generally headaches were treated with paracetamol
(acetaminophen), aspirin or non-steroidal anti-inflam-
matory drugs (NSAID). Opiates and analgesics containing
caffeine were avoided or discontinued wherever possible.
Surgical treatment was undertaken if there was significant
risk of progressive visual loss despite medical treatment
either due to lack of efficacy, intolerance or non-compli-
ance. Lumbo-peritoneal shunt was the preferred option,
unless the cerebellar tonsils were relatively low, in which
case ventriculoperitoneal shunt was performed. Optic
nerve sheath fenestration was performed if there was no
associated headache or the patient declined a CSF shunt.
We applied 2 exclusion criteria for the review: 1 for preg-
nancy and 1 for previous surgery. Patients who were preg-
nant at presentation or had a pregnancy recorded in the
notes less than 1 year after stopping systemic treatment
were excluded since there would be reasonable grounds to
suggest that the pregnancy had influenced the treatment
course. With regards to surgery, patients having had a pro-
cedure for IIH during the time of follow-up that led to a
cessation of treatment were excluded. However those who
had a procedure to manage IIH many years before pre-
senting to our clinic or those whose systemic treatment
continued unchanged before and after their procedure
were included.
The study patients were divided according to the length of
time between first and last recorded clinic appointment.
The data was sequentially analysed as 3 groups: those
patients with follow-up data for 24 months or more from
presentation, those with follow-up data for 18 months or
more from presentation (which would include all the
patients in the 24 month group) and those with follow-up
data for 12 months or more (which would include all the
patients above). Since the groups were summative, the 12
month group was the largest. As discussed in the introduc-
tion, there are limitations associated with using both
symptomatology and objective clinical findings as indica-
tors of disease stage in IIH. In searching for a more robust
measure of overall clinical improvement we therefore
divided the patients for each follow-up group simply
according to whether they were on treatment or not on
treatment at most recent review. Reflecting the practice of
a single neuro-ophthalmologist, the patients' weights
were consistently not referred to in making decisions
regarding treatment. No other patient parameters were
considered in the analysis. We did not subdivide the
patients according to the specific treatment prescribed but
only the absolute treatment status. The patients who hadPage 2 of 6
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were separated from those who had gained weight. The 4
groups for each period of follow-up were cross-tabulated
and analysed using Fisher's exact tests for significance.
Since the patient's treatment status at their last review was
taken as the single measure of disease behaviour, patients
who never required treatment were included in the 'not
on treatment at most recent review' groups. Survival
curves were plotted to determine the probability of stop-
ping treatment having lost weight over time and the sig-
nificance of the difference between the curves calculated
using a log rank test.
Results
The notes of 70 patients who had presented sequentially
to a single consultant's neuro-ophthalmology practice
between February 1998 and March 2003 were retrieved.
41 IIH patients were eligible for inclusion with follow-up
of 12 months or greater. All patients met the modified
Dandy criteria with secondary causes of raised intracranial
pressure excluded using appropriate investigations.
3 patients had surgical interventions (all lumbo-perito-
neal shunts) leading to systemic treatment being stopped
and were excluded. 2 patients were included with a surgi-
cal intervention. 1 had optic nerve sheath fenestration in
1992 and presented in 1999 and 1 had optic nerve sheath
fenestration during the follow-up period but medical
treatment remained unchanged before and after surgery. 2
patients were excluded who became pregnant within 12
months of stopping treatment. 2 patients were included
who became pregnant during the follow-up period but
the pregnancy was recorded in the notes 18 months or
more after systemic treatment was stopped. We therefore
assume that the 2 events are unrelated. 36 patients were
therefore included in the analysis, 35 female and 1 male.
Mean age at presentation was 31.6 yrs (standard deviation
= 10.1 yrs) and mean BMI at presentation was 36.6 kg/m2
(standard deviation = 7.5 kg/m2). Mean length of follow-
up was 30 months (standard deviation = 16.3 months).
One patient had weights but not height recorded. She is
therefore included in the cross-tabulations but not the sta-
tistics that require BMIs.
The cross-tabulations are shown in table 1 with corre-
sponding p-values from Fisher's exact tests. The cross-tab-
ulation for 12 months or more follow-up contains all 36
patients. 24 of these patients had 18 months or more fol-
low-up and 19 of these patients had 24 months or more
follow-up, and were cross-tabulated accordingly. There
were no patients with identical BMIs at first and last
reviews.
There must be no statistically significant difference
between the patients leaving the analysis at each time
point and those remaining or the results will be skewed.
We divided the patients into 3 groups (different from
those used for the cross-tabulation): patients leaving the
analysis before the 18 month follow-up point (Group A:
12 patients), patients with between 18 and 23 months
inclusive follow-up, i.e. leaving between the 18 and 24
month follow-up points (Group B: 5 patients) and
patients with 24 months or greater follow-up (Group C:
19 patients). Using Mann-Whitney U-tests, there was no
difference in BMI distributions at presentation when com-
paring Group C to Group A (p = 0.14) or Group B (p =
0.41). Similarly there was no significant difference
between the 3 groups at 12 months follow-up (Group A
vs Group C: p = 0.09, Group B vs Group C: p = 0.91) and
no significant difference between Group B and C at 18
months follow-up (p = 0.73).
We also divided the patients into all those on treatment at
their last review (n = 21) to all those not on treatment at
last review (n = 16) to ensure that the 2 groups were oth-
erwise comparable. The results are shown in table 2. There
is no statistically significant difference between the groups
with regard to age, opening pressure, length of follow up
or BMI at presentation.
The survival analysis for the patients is demonstrated in
figure 1. Since the end point for the analysis was stopping
treatment, the patients who were never on treatment or
who were followed up for a period before starting treat-
ment were excluded (5 of 36 patients). We divided the
remaining 31 patients into gained weight and lost weight
groups disregarding the patient's treatment status at last
review. In the gained weight group 6 patients had less
than 24 months follow-up and 9 patients had 24 months
Survival analysis demonstrating the probability of being on treatment having gained weight and the probability of bei g on tre tment having lost we ght over timeFigure 1
Survival analysis demonstrating the probability of being on 
treatment having gained weight and the probability of being 
on treatment having lost weight over time. The end point for 
the analysis was stopping treatment.Page 3 of 6
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had less than 24 months follow-up and 3 patients had 24
months or more follow-up. The survival analysis demon-
strates that the probability of being on treatment at 5 years
follow-up having gained weight is 0.63 whereas the prob-
ability having lost weight is 0.38. Significance testing the
difference between the 2 curves with a log rank test returns
p = 0.04.
We can draw inferences on the amount of weight loss
required to stop treatment if we consider only the patients
who lost weight (18 of the total 36 patients, excluding the
patient with weights but not BMIs: see table 1) and com-
pare those on treatment at the most recent follow-up (9
patients) to those not on treatment at the most recent fol-
low-up (9 patients). The data are presented in table 3.
There is no significant difference between those on treat-
ment and those not on treatment with regard to final
weight in kilogrammes (Mann Whitney U, p = 0.22) or
weight lost in kilogrammes (Mann Whitney U, p = 0.19).
Similarly there is no significant difference between the 2
groups when comparing the change in BMIs between first
and last reviews (Mann Whitney U, p = 0.26). However
the difference between the groups is significant when
comparing the final BMIs (Mann Whitney U, p = 0.05).
The average final BMI in the group remaining on treat-
ment at last review was 37.6 kg/m2 (95% confidence inter-
val: 30.6 kg/m2, 44.7 kg/m2) whereas the average final
BMI in the group not on treatment at last review was 30.2
kg/m2 (95% confidence interval: 25.2 kg/m2, 35.2 kg/m2)
Discussion and conclusion
Our results demonstrate an association between weight
loss and stopping systemic treatment but only after 24
months of follow up. The results suggest that the groups
of patients leaving the statistical analysis at each time
point are representative of the group as a whole with
regard to baseline BMIs and change in BMIs over time.
The only significant difference between the groups at each
time point from the data collected is therefore length of
follow-up and consequently amount of weight lost. The
difference between the weight loss and weight gain groups
Table 1: Cross-tabulations for 12 months and above, 18 months and above and 24 months and above follow-up groups with p-values 
from Fisher's exact tests
Length of follow-up Patient's BMI change 
comparing initial to most 
recent review
Patients on treatment at 
most recent review
Patients not on treatment 
at most recent review
12 months and above
BMI increase 12 5
BMI decrease 9 10 n = 36
p = 0.14
18 months and above
BMI increase 8 4
BMI decrease 4 8 n = 24
p = 0.11
24 months and above
BMI increase 8 4
BMI decrease 1 6 n = 19
p = 0.04
Table 2: Comparing all the patients on treatment at most recent review to all the patients not on treatment at most recent review 
with regards to parameters indicated
Patients on treatment at 
most recent review
Patients not on treatment at 
most recent review
Mann Whitney U test
Age/years (standard deviation) 32.0 (10.6) 31.2 (10.4) p = 0.82
Sex 21 female 14 female: 1 male
Opening pressure/cm H2O 
(standard deviation)
35.9 (11.4) 34.2 (10.4) p = 0.66
Length of follow up/months 
(standard deviation)
32.1 (15.5) 32.8 (15.5) p = 0.90
Body mass index at presentation/
kg/m2 (standard deviation)
38.0 (8.0) 34.4 (6.4) p = 0.17Page 4 of 6
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cantly lower probability of being on treatment at 5 years
follow-up having lost weight. Unlike previous studies, the
results suggest that rather than an average amount of
weight loss being associated with improvement, the final
absolute BMI is more important for patients stopping
treatment.
One previous study comparing weight loss to improve-
ment in objective clinical findings found a significant
improvement in papilloedema grade in the patient's worst
eye at baseline when comparing the papilloedema grade
at the last recorded clinic review of a group of patients
who lost 2.5 kg or more over any 3 month interval during
follow-up to a group who lost less than 2.5 kg over any 3
month period1. The last clinic review was classified as
being more than 6 months from presentation in all
patients. There was no association between weight loss
and improved visual function or visual fields. There was
also no correlation between amount of weight loss and
degree of papilloedema improvement. Only Johnson et
al.[9] to date have demonstrated a qualitative association
between weight loss and papilloedema resolution report-
ing that a 6.2% weight loss (standard error of the mean =
0.6%) was significantly associated with a 3 grade
improvement in papilloedema using a modified Frisén
scale [13] and masked graders. Our study is the first to use
the decision to stop treatment taken independently of the
patient's weight as a measure of overall clinical improve-
ment. We have attempted to be rigorous in using the
patient's treatment status as the sole outcome variable and
thus avoid the problems associated with using objective
clinical findings or symptomatology to monitor disease
remission, as discussed in the introduction. Our study
agrees with previous work demonstrating the importance
of weight loss. However our results disagree by suggesting
that final BMI is more important than the drop in BMI
when considering patients who stop treatment.
We must offer a hypothesis for why 24 months of follow-
up was required for our weight loss group. We assume that
following our weight control protocol takes 24 months
for a significant proportion of our patients to lose weight
and for treatment then to be stopped. Therefore, although
the length of time required will probably be different for
different departments, this does not negate the suggestion
that weight loss offers continuing benefit with regard to
remaining off treatment, with the cumulative effect of
steady weight loss manifesting as increasing statistical sig-
nificance over time for both the Fisher's exact tests and
survival analysis. This is not merely an example of pro-
longed follow-up leading to an inevitable trial discontin-
uation of treatment or spontaneous disease remission by
24 months for if this was the case then there should be no
difference at all between the weight gained and weight lost
groups at the 24 month point. We also note however that
since this is an uncontrolled study, we are unable to com-
ment further on the natural history of the disease.
Due to problems in the past with monitoring IIH objec-
tively, we suggest that discontinuation of systemic treat-
ment is a robust measure of improvement in the overall
clinical condition provided that decisions regarding the
patient's treatment are consistently taken independently
of their current weight, as in this study. Although the
pathophysiological link between body mass and the risk
of developing IIH demonstrated epidemiologically
remains unclear, we hope that our study contributes use-
ful evidence to the debate regarding the benefit of weight
loss for IIH patients.
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